In alignment with its suggested key role in antigen presentation, pharmacologic or genetic inhibition of cathepsin S in preclinical models alleviates pathogenic symptoms in various autoimmune diseases such as multiple sclerosis and arthritis (12, 14, 15). The gene discussed is CTSS; the disease is multiple sclerosis.